Matthew Burke on Immune-Mediated Adverse Events

MATTHEW BURKE, MBA, RN, MSN, APRN-BC | May 05, 2014
Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carcinoma, Yale New Haven Hospital, discusses managing immune-mediated adverse events (IMAEs).

Burke says there are not great guidelines for managing IMAEs. The most common IMAEs are colitis, dermatitis, endocrinopathies and hepatotoxicity. Burke says the key to managing these side effects is early intervention, close monitoring and supportive treatment or steroids when necessary.

Using steroids to treat these side effects are "more of an art than science," Burke says. In some cases, steroids will not work, especially in autoimmune colitis or autoimmune hepatitis. In this instance, nurses can use adjunct therapies such as infliximab or mycophenolate, Burke says.

Burke says it is important for nurses to know and understand the principles behind IMAEs.

<<< View more from the 2014 ONS Annual Congress



External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Blogs
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2017
Intellisphere, LLC. All Rights Reserved.